Where editors, bloggers and marketers get licensed, republishable content.

Show Advanced

Biotech venture capital investments in public equities and performance

How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds? While anecdotal evidence points to some really successful investments (e.g. Abingworth's investment in Algeta in February 2009 (24x deal return)), this analysis of a large sample of VIPEs in the biotechnology and pharmaceutical industry over the…

To republish, copy/paste this to your site (ads inserted):

By doing so, you agree to the terms of use.

Copy code